**Study Purpose**: This study is looking at how safe and tolerable a drug called **talquetamab** is when combined with other cancer treatments for people with **multiple myeloma**. Multiple myeloma is a type of blood cancer. The goal is to find a safe dose of talquetamab when used in these combinations. **Eligibility**: To join, participants must have a confirmed diagnosis of multiple myeloma, show signs of the disease through specific tests, and be generally healthy based on a performance status score. Women who can have children must show a negative pregnancy test. Participants must agree to follow rules about lifestyle and medication safety plans. **Key Points**: - **Study Length & Visits**: Participants will need to commit to multiple visits, but the exact number isn't specified. - **Compensation & Treatment**: Information on compensation isn't provided; treatment involves talquetamab with other therapies. - **Potential Risks**: Participants cannot have had certain recent vaccines, high doses of steroids, or a history of certain health issues like CNS involvement, HIV, stroke, or seizures. If you have multiple myeloma and meet the criteria, consider discussing participation with your doctor.